MedTrace Logo

Treatment of Latent Autoimmune Diabetes of the Adult

NCT01140438 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 64

Last updated 2020-01-10

No results posted yet for this study

Summary

The purpose of the study is to clarify whether patients classified as Latent autoimmune diabetes of the adult (LADA) benefit from early treatment with insulin added to per oral treatment and lifestyle measures.

Conditions

Interventions

DRUG

metformin+ NPH insulin

Metformin 500 mg + 500 mg + 1000 mg NPH insulin , initially 0.20 U/kg body weight.

DRUG

metformin + sitagliptin +/- repaglinide

Metformin 500 mg + 500 mg + 1000 mg Sitagliptin 100 mg x 1 Repaglinide 1 mg x 3

Sponsors & Collaborators

  • Norwegian University of Science and Technology

    lead OTHER

Principal Investigators

  • Valdemar Grill, med phd · Department of Cancer Research and Molecular Medicine

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
30 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-03-31
Primary Completion
2018-11-30
Completion
2018-11-30

Countries

  • Norway

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01140438 on ClinicalTrials.gov